Navigation Links
Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
Date:8/19/2008

las.org" target="_new">http://www.proteinatlas.org). Prestige Antibodies are optimized on a single protocol and are tailored for high throughput operations, providing the potential for significant time and cost savings for researchers.

Sigma-Aldrich is committed to building antibody content for life science researchers through collaborations and an appreciable expansion of its internal antibody production. Earlier this year, the company announced a partnership with AbD Serotec, a Division of MorphoSys, to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD technology. Sigma-Aldrich recently entered into a five-year collaboration with the University of California, San Francisco, (UCSF) to develop optimal cell lines for the production of monoclonal antibodies.

Prestige Antibodies(TM) are available at http://www.sigma.com/prestige, where customers can search or browse for available antibodies by specific gene name and ID, or by keywords.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldr
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend
2. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
3. Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
4. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
5. Video: Allen Institute for Brain Science Unveils Worlds First Genome-Wide Spinal Cord Atlas
6. Atlas Spine Launches Stature(TM) Vertebral Body Replacement System
7. Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas
8. Atlas Spine Releases Back-PAK(TM) Discectomy Set
9. INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement
10. Fractured Atlas Offers Affordable Aetna Advantage Plans for Artists
11. MU research team releases first Missouri Hunger Atlas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... and myeloproliferative disorders are serious and often deadly ... Annual Meeting of the American Society of Hematology ... methods for patients suffering from acute promyelocytic leukemia, ... myelofibrosis that are based on a better understanding ...
(Date:12/5/2009)... being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- ... without ever tying the knot, since research has shown that ... um, isn,t there something wrong with those who go it ... looking at psychological measures shows that never-married people aged 40 ...
(Date:12/5/2009)... innovative new international private medical insurance plan which follows the acclaimed ... the flexibility to add or remove a wide range of options ... tailor their benefits to complement those already offered in their country ... ...
(Date:12/5/2009)... to do everything from growing mushrooms, making wine to keeping prisoners in ... ... that your wine, water and vegetables would have come from Wind Turbines? ... turbines, for industry end users, not wind farms. "Using a technology ...
(Date:12/4/2009)... YORK, Dec. 4 Care Investment Trust Inc. (NYSE: ... its Board of Directors has declared a dividend of $0.17 per ... 22, 2009 to common shareholders of record on December 14, 2009. ... Care Investment Trust Inc. is a real estate investment and finance ...
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... Offers Fun and Wallet-Friendly Tips for Enjoying the ... makers of BENADRYL(R) and the National Park Foundation ... everyone, including people with allergies, to pledge to ... and family.(Photo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01084 ...
... 25, 2009 BALTIMORE, April 20 The first annual ... gaining national support. The day is meant to raise ... the Meningococcal disease. "We recognize the dangers of meningitis ... said Fran Lessans, CEO of Passport Health, the largest ...
... Spring with Fresh, New Colors from Z-CoiL® , ... Albuquerque, NM (PRWEB) ... of our unique line of Pain Relief Footwear® products, ushers in spring ... Women. There is currently only a limited supply of these new athletic ...
... TOKYO, April 20 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., ... Kagaku Kenkyusho Co.,Ltd. (SKK), a pharmaceutical company headquartered ... into a strategic alliance. The partnership,was formed as ... SKK to target the,Asian market, in step with ...
... could prevent radiation-induced leukemia, according to data presented at ... 2009. , Alexandra Miller, Ph.D., a senior scientist ... research is designed to help military and space agency ... risky levels of radiation than the general population. However, ...
... can help control appetite and weight , , SUNDAY, April 19 ... on snacking by chewing more sugarless gum. , ... three hours after a standard lunch and were told they ... One afternoon the participants also chewed sugarless gum for 15 ...
Other Medicine News:Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 2Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 3Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 4Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 5Health News:First Annual World Meningitis Day Gaining National Support 2Health News:Got the Blues? Get Z-CoiL Pain Relief Shoes 2Health News:Shanghai ChemPartner and SKK Announce Strategic Alliance 2Health News:Gum Chewing May Cut Craving for Snacks 2
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... chemical threats, announced today that the Company is ... of Valortim® in an inhalation anthrax model in ... data are being presented during an oral session ...
(Date:12/4/2009)... HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers ... an acceleration device to enhance orthodontics, announced the ... by PennWell Corporation , a leader in ... dentistry. The course focuses on patient views ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawford presented results ... of secondary end points of biochemical recurrence rate in ... for injection) or monthly leuprolide in prostate cancer patients ... patients who received FIRMAGON 240/80 mg/month had a recurrence ...
Breaking Medicine Technology:PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 1Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 1BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 3Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 1Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... Pacemaker Follow-Up Solution makes convenience and ... our Cardiac Monitoring Center, qualified professionals ... seven days a week for Pacemaker ... time they experience a problem or ...
Medicine Products: